UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 12, 2022 (
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
(State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
(Address of principal executive offices) |
|
(Zip Code) |
(
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
The information set forth below, including Exhibit 99.1, is incorporated by this reference.
Item 7.01. Regulation FD Disclosure.
As previously announced, Tivity Health, Inc. (the “Company”) will participate in the 40th Annual J.P. Morgan Healthcare Conference, which will be held virtually January 10-13, 2022. The Company’s President and Chief Executive Officer, Richard Ashworth, will make a presentation on Thursday, January 13 at 7:30 a.m. E.T., using the slides attached hereto as Exhibit 99.1 and incorporated by this reference, followed by a question-and-answer session including Adam Holland, Chief Financial Officer, and Tommy Lewis, Chief Operating Officer. A live audio-only webcast and replay of the event will be available on the "Investors" section of the Company's website, www.tivityhealth.com.
The information furnished pursuant to this Item 7.01 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
|
|
|
|
|
|
Exhibit 99.1 |
|
|
|
|
|
|
|
Exhibit 104 |
|
Cover Page Interactive Date File (embedded within the Inline XBRL document) |
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
TIVITY HEALTH, INC. |
||
|
|
|
||
|
|
By: |
|
/s/ Adam Holland |
|
|
|
|
Name: Adam Holland |
|
|
|
|
Title: Chief Financial Officer |
Date: January 12, 2022